Financial reports

Home » Investors » Financial reports

Contact

e-mail: info@ziccum.com

ZICCUM AB
Scheelevägen 22
223 63 LUND
Sweden

About us

Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and also are highly suitable for novel administration routes.

Subscribe

Receive company data continuously to your inbox

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok